Proteomic landscape of Alzheimer's Disease: novel insights into pathogenesis and biomarker discovery
Mass spectrometry-based proteomics empowers deep profiling of proteome and protein
posttranslational modifications (PTMs) in Alzheimer's disease (AD). Here we review the …
posttranslational modifications (PTMs) in Alzheimer's disease (AD). Here we review the …
Extracellular protein components of amyloid plaques and their roles in Alzheimer's disease pathology
Alzheimer's disease (AD) is pathologically defined by the presence of fibrillar amyloid β (Aβ)
peptide in extracellular senile plaques and tau filaments in intracellular neurofibrillary …
peptide in extracellular senile plaques and tau filaments in intracellular neurofibrillary …
Large-scale deep multi-layer analysis of Alzheimer's disease brain reveals strong proteomic disease-related changes not observed at the RNA level
The biological processes that are disrupted in the Alzheimer's disease (AD) brain remain
incompletely understood. In this study, we analyzed the proteomes of more than 1,000 brain …
incompletely understood. In this study, we analyzed the proteomes of more than 1,000 brain …
Compilation of reported protein changes in the brain in Alzheimer's disease
M Askenazi, T Kavanagh, G Pires… - Nature …, 2023 - nature.com
Proteomic studies of human Alzheimer's disease brain tissue have potential to identify
protein changes that drive disease, and to identify new drug targets. Here, we analyse 38 …
protein changes that drive disease, and to identify new drug targets. Here, we analyse 38 …
The amyloid plaque proteome in early onset Alzheimer's disease and Down syndrome
Amyloid plaques contain many proteins in addition to beta amyloid (Aβ). Previous studies
examining plaque-associated proteins have shown these additional proteins are important; …
examining plaque-associated proteins have shown these additional proteins are important; …
Deep proteomic network analysis of Alzheimer's disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease
Background The complicated cellular and biochemical changes that occur in brain during
Alzheimer's disease are poorly understood. In a previous study we used an unbiased label …
Alzheimer's disease are poorly understood. In a previous study we used an unbiased label …
Systems-based proteomics to resolve the biology of Alzheimer's disease beyond amyloid and tau
S Rayaprolu, L Higginbotham, P Bagchi… - …, 2021 - nature.com
The repeated failures of amyloid-targeting therapies have challenged our narrow
understanding of Alzheimer's disease (AD) pathogenesis and inspired wide-ranging …
understanding of Alzheimer's disease (AD) pathogenesis and inspired wide-ranging …
[HTML][HTML] Identification of molecular signatures and pathways to identify novel therapeutic targets in Alzheimer's disease: Insights from a systems biomedicine …
Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by the
accumulation of amyloid plaques and neurofibrillary tangles in the brain. However, there are …
accumulation of amyloid plaques and neurofibrillary tangles in the brain. However, there are …
Alzheimer's disease-associated U1 snRNP splicing dysfunction causes neuronal hyperexcitability and cognitive impairment
Recent proteome and transcriptome profiling of Alzheimer's disease (AD) brains reveals
RNA splicing dysfunction and U1 small nuclear ribonucleoprotein (snRNP) pathology …
RNA splicing dysfunction and U1 small nuclear ribonucleoprotein (snRNP) pathology …
Pathological tau drives ectopic nuclear speckle scaffold protein SRRM2 accumulation in neuron cytoplasm in Alzheimer's disease
PJ McMillan, TJ Strovas, M Baum, BK Mitchell… - Acta Neuropathologica …, 2021 - Springer
Several conserved nuclear RNA binding proteins (sut-1, sut-2, and parn-2) control tau
aggregation and toxicity in C. elegans, mice, and human cells. MSUT2 protein normally …
aggregation and toxicity in C. elegans, mice, and human cells. MSUT2 protein normally …